Brief: Panbela Therapeutics Received Notice Of Delisting Or Failure To Satisfy A Standard From Nasdaq
01/12/2023 21:40
Dec 1 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA THERAPEUTICS INC: RECEIVED NOTICE OF DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ ON NOVEMBER 28, 2023
Source text for Eikon: ID:
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants